CBU
CRNX icon

CIBC Bancorp USA’s Crinetics Pharmaceuticals CRNX Stock Holding History

CIBC Bancorp USA’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+5,727
New +$213K ﹤0.01% 1741
2025
Q3 		$401K Buy
+9,639
New +$308K ﹤0.01% 957

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

CIBC Bancorp USA's CRNX Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 5,727 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #1741 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in CRNX as recently as Q3 2025.

CIBC Bancorp USA first reported a position in CRNX in Q3 2025 and has held it in 2 quarters since. The position peaked at $401K in Q3 2025. 250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • CIBC Bancorp USA held 5,727 shares of Crinetics Pharmaceuticals worth $214K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new CIBC Bancorp USA position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1741 holding.
  • CIBC Bancorp USA first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • CIBC Bancorp USA's Crinetics Pharmaceuticals position peaked at $401K in Q3 2025.
  • 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.